2006
DOI: 10.1016/j.cardfail.2005.11.011
|View full text |Cite
|
Sign up to set email alerts
|

Section 6: Nonpharmacologic Management and Health Care Maintenance in Patients With Chronic Heart Failure

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
4
0

Year Published

2010
2010
2023
2023

Publication Types

Select...
5
2

Relationship

0
7

Authors

Journals

citations
Cited by 19 publications
(4 citation statements)
references
References 86 publications
0
4
0
Order By: Relevance
“…Although the assessment of 24-hour urine sodium excretion is considered the gold standard method, the measurement of spot uNa could provide an approximate estimate of sodium excretion, with increased convenience and low cost [ 25 , 29 , 31 - 34 ]. On the other hand, a previous study demonstrated that spot uNa was reduced by decongestive therapy for advanced HF, which might provide insightful information to titrate the diuretic dose [ 35 , 36 ]. Hence, in general, decreased uNa in HF patients can be a result of low salt intake or effective diuretic therapy [ 35 ].…”
Section: Discussionmentioning
confidence: 99%
“…Although the assessment of 24-hour urine sodium excretion is considered the gold standard method, the measurement of spot uNa could provide an approximate estimate of sodium excretion, with increased convenience and low cost [ 25 , 29 , 31 - 34 ]. On the other hand, a previous study demonstrated that spot uNa was reduced by decongestive therapy for advanced HF, which might provide insightful information to titrate the diuretic dose [ 35 , 36 ]. Hence, in general, decreased uNa in HF patients can be a result of low salt intake or effective diuretic therapy [ 35 ].…”
Section: Discussionmentioning
confidence: 99%
“…All authors, including three ED physicians (two attending, one resident) and two non-clinician researchers (one human factors engineer, one social scientist), reviewed the literature and suggested for the instrument barriers identified in clinical guidelines 38-42 or across multiple systematic reviews and individual articles. 10,15,29,31,43-55 A few less commonly reported barriers were added because they were identified in the research team's concurrent study of chronic heart failure patients.…”
Section: Methodsmentioning
confidence: 99%
“…Zick et al, 2008 77 Significant improvement in maximal workload using bicycle ergometry 69,70 Increase in exercise tolerance 68,70 Reduction of the pressure×heart rate product (systolic blood pressure in mm Hg times heart rate per min and divided by 100) 70,71,73,78 Improvement in HF symptoms (eg, dyspnea, fatigue, palpitations) Theoretical potentiation of coronary and peripheral vasodilators 79 Conflicting evidence on interaction with digoxin 79,80 Appears to be safe when used in combination with angiotensinconverting enzyme inhibitors, β-blockers 67,79 Generally well tolerated with mild-to-moderate side effects 64 Cardiac (eg, palpitations, chest pain) 71,72 Gastrointestinal concerns 69,71,72 Neurological (eg, dizziness, migraine, headache) 69,71 Influenza-like symptoms 67,69 Potential increased risk of orthostatic hypotension 79 Potential increased risk of arrhythmia 79 Insufficient informa- Keith et al, 2019 94 Schoenenberger et al, 2012 95 Smithline et al, 2007 96 Shimon et al, 1995 97 Improvement in LVEF after 7 d of IV thiamine compared with baseline but not compared with placebo with long-term furosemide therapy 97 Significant improvement in LVEF in symptomatic chronic HFrEF 43 No major harm…”
Section: Coenzyme Q10/ubiquinone/ubiquinolmentioning
confidence: 99%
“…Zick et al, 2008 77 Significant improvement in maximal workload using bicycle ergometry 69,70 Increase in exercise tolerance Theoretical potentiation of coronary and peripheral vasodilators 79 Conflicting evidence on interaction with digoxin 79,80 Appears to be safe when used in combination with angiotensinconverting enzyme inhibitors, β-blockers 67,79 Generally well tolerated with mild-to-moderate side effects 64 Cardiac (eg, palpitations, chest pain) 71,72 Gastrointestinal complaints 69,71,72 Neurological (eg, dizziness, migraine, headache) 69,71 Influenza-like symptoms 67,69 Potential increased risk of orthostatic hypotension 79 Potential increased risk of arrhythmia 79 Insufficient The HOPE and HOPE-TOO Trial Investigators 183 Marchioli et al, 2006 184 Chae et al, 2012 185 In the Women's Health Study, 185 women aged >45 y randomly assigned to vitamin E 600 IU every other day was not associated with increased risk for systolic HF. A prespecific subgroup analysis showed a 40% reduction in the risk of HF with preserved ejection fraction.…”
Section: Yogamentioning
confidence: 99%